Updated Clinical Data on ARIAD's Investigational pan-BCR-ABL Inhibitor, Ponatinib, to Be Presented at Annual American Society of Hematology Meeting

Company to Host Investor Meeting and Webcast with Dr. Hagop M. Kantarjian on Sunday, December 5 at 7 a.m.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) being held in Orlando, Florida, December 4-7, 2010. These Phase 1 findings in patients with resistant and refractory chronic myeloid leukemia (CML) will be featured in an oral presentation and will also be highlighted in a webcast investor meeting being held at ASH.

The schedule and locations for the investor meeting and oral presentation session are listed below:

Investor Meeting and Webcast:

A breakfast meeting to review the updated ponatinib data with research analysts and institutional investors will feature Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, and members of ARIAD’s management. This meeting will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com.

Date and Time: Sunday, December 5, 2010, 7:00 – 8:00 a.m. ET

Location: Hilton Orlando Hotel, Lucerne Conference Room

To attend the meeting in person, please RSVP in advance by Friday, December 3, 2010 by responding to [e-mail].

A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least fifteen minutes prior to the scheduled start time.

Presentation of Data:

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Presenter: Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia at the University of Texas MD Anderson Cancer Center

Oral Session: Chronic Myeloid Leukemia - Therapy: Optimizing Treatment Outcome

Date and Time: Monday, December 6, 2010, 8:15 a.m. ET

Location: Orange County Convention Center, Valencia A

About ARIAD

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD’s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in pivotal Phase 2 clinical development in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit http://www.ariad.com.